Onyx' potential blockbuster for multiple myeloma Kyprolis wins early US FDA approval
This article was originally published in Scrip
Executive Summary
Multiple myeloma patients who may have run out of hope have a new treatment option that may add months to their lives now that the US FDA has granted accelerated approval to Onyx Pharmaceuticals' intravenous product Kyprolis (carfilzomib), which could become a blockbuster drug.